JP2022023223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022023223A5 JP2022023223A5 JP2021182945A JP2021182945A JP2022023223A5 JP 2022023223 A5 JP2022023223 A5 JP 2022023223A5 JP 2021182945 A JP2021182945 A JP 2021182945A JP 2021182945 A JP2021182945 A JP 2021182945A JP 2022023223 A5 JP2022023223 A5 JP 2022023223A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- ngf antibody
- human ngf
- antibody fab
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016061353 | 2016-03-25 | ||
| JP2016061353 | 2016-03-25 | ||
| JP2018507426A JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| PCT/JP2017/011910 WO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ'フラグメント含有医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507426A Division JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022023223A JP2022023223A (ja) | 2022-02-07 |
| JP2022023223A5 true JP2022023223A5 (https=) | 2022-12-16 |
| JP7215555B2 JP7215555B2 (ja) | 2023-01-31 |
Family
ID=59900467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507426A Pending JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| JP2021182945A Active JP7215555B2 (ja) | 2016-03-25 | 2021-11-10 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507426A Pending JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200299371A1 (https=) |
| EP (1) | EP3434283A4 (https=) |
| JP (2) | JPWO2017164349A1 (https=) |
| KR (1) | KR20180123559A (https=) |
| CN (1) | CN108883177A (https=) |
| CA (1) | CA3018473A1 (https=) |
| MX (1) | MX2018011675A (https=) |
| PH (1) | PH12018501978A1 (https=) |
| RU (1) | RU2018137495A (https=) |
| SG (1) | SG11201808119UA (https=) |
| TW (1) | TW201738269A (https=) |
| WO (1) | WO2017164349A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
| CA3115747A1 (en) * | 2018-10-10 | 2020-04-16 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| EP4710949A1 (en) * | 2023-05-12 | 2026-03-18 | Goryo Chemical, Inc. | Lyophilized preparation, lyophilized solution, methods for producing same, and liquid agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| CN102159204B (zh) | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
| PE20130203A1 (es) * | 2010-03-17 | 2013-03-24 | Abbott Res Bv | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) |
| PT2743348T (pt) * | 2011-08-11 | 2018-02-23 | Astellas Pharma Inc | Novo anticorpo anti-ngf humano |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
-
2017
- 2017-03-24 JP JP2018507426A patent/JPWO2017164349A1/ja active Pending
- 2017-03-24 MX MX2018011675A patent/MX2018011675A/es unknown
- 2017-03-24 CA CA3018473A patent/CA3018473A1/en not_active Abandoned
- 2017-03-24 CN CN201780019929.0A patent/CN108883177A/zh active Pending
- 2017-03-24 SG SG11201808119UA patent/SG11201808119UA/en unknown
- 2017-03-24 RU RU2018137495A patent/RU2018137495A/ru unknown
- 2017-03-24 US US16/087,908 patent/US20200299371A1/en not_active Abandoned
- 2017-03-24 EP EP17770389.9A patent/EP3434283A4/en not_active Ceased
- 2017-03-24 WO PCT/JP2017/011910 patent/WO2017164349A1/ja not_active Ceased
- 2017-03-24 TW TW106109999A patent/TW201738269A/zh unknown
- 2017-03-24 KR KR1020187030401A patent/KR20180123559A/ko not_active Ceased
-
2018
- 2018-09-13 PH PH12018501978A patent/PH12018501978A1/en unknown
-
2021
- 2021-11-10 JP JP2021182945A patent/JP7215555B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022023223A5 (https=) | ||
| JP2024099682A5 (https=) | ||
| RU2519031C1 (ru) | Жидкие препаративные формы для длительно действующего конъюгата g-csf | |
| JP5946448B2 (ja) | 持続型ヒト成長ホルモン結合体液状製剤 | |
| TWI738632B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| ES2700925T3 (es) | Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada | |
| RU2600847C2 (ru) | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина | |
| ES2565543T3 (es) | Construcciones de fusión a Fc de unión a fosfatidilserina y su uso terapéutico | |
| TWI494120B (zh) | 長效α－型干擾素接合物之液體調配物 | |
| ES2734076T3 (es) | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada | |
| JP2021503485A5 (https=) | ||
| TWI848956B (zh) | 包含vegf拮抗物之液體組成物 | |
| KR20220024914A (ko) | 분지형 링커를 사용한 세포독성제 대 세포 결합 분자의 접합체 | |
| FI3576788T3 (fi) | Matalan ph-arvon omaava farmaseuttinen koostumus, joka käsittää t-soluihin sitoutuvia vasta-ainekonstrukteja | |
| JP2021503485A (ja) | ＶＥＧＦＲ−Ｆｃ融合タンパク質製剤 | |
| CN101312744A (zh) | 免疫球蛋白融合蛋白制剂 | |
| JP2022523103A (ja) | 分岐連結体とアマニタトキシンとの共役体 | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP2019501139A (ja) | 医薬製剤及びその使用 | |
| JP2018115166A (ja) | 持続型ヒト成長ホルモン結合体の高濃度液剤 | |
| JP2019532267A5 (https=) | ||
| JP7215555B2 (ja) | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 | |
| KR20230019089A (ko) | 바이러스 감염을 치료하기 위한 계면활성제 단백질 d의 용도 | |
| CN107073080A (zh) | 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂 | |
| CN112312890A (zh) | 稳定的杂合fc融合g-csf制剂 |